Patrick MacDonald Fisher
Overview
Explore the profile of Patrick MacDonald Fisher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
328
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jensen K, Dam V, Kohler-Forsberg K, Ozenne B, Stenbaek D, Ganz M, et al.
J Psychiatr Res
. 2024 Dec;
181():197-205.
PMID: 39616866
Serotonin reuptake inhibitors have been reported to increase hippocampal volume and improve memory function in patients with Major depressive disorder (MDD). The postsynaptic 5-HT4 receptor (5-HT4R) is involved in hippocampal...
2.
Bruzzone S, Ozenne B, MacDonald Fisher P, Ortega G, Jorgensen M, Knudsen G, et al.
Prog Neuropsychopharmacol Biol Psychiatry
. 2024 Oct;
136():111160.
PMID: 39368538
Selective serotonin reuptake inhibitors (SSRI) are frequently ineffective in treating depressive episodes and biomarkers are needed to optimize antidepressant treatment outcomes. DNA methylation levels of serotonin transporter (SLC6A4) and tryptophan...
3.
Hovmand O, Korsbak Madsen M, MacDonald Fisher P, Stenbaek D
J Psychopharmacol
. 2024 Aug;
38(10):924-932.
PMID: 39135498
Background: Psychedelic substances reliably induce marked altered states of consciousness (ASC), which may be important for lasting effects and clinical outcomes of psychedelic intervention. Several instruments are available to measure...
4.
Zarifkar P, Wagner M, MacDonald Fisher P, Stenbaek D, Berg S, Knudsen G, et al.
Brain Commun
. 2024 Jul;
6(4):fcae174.
PMID: 39045091
Survival rates after out-of-hospital cardiac arrest have improved over the past two decades. Despite this progress, long-term cognitive impairment remains prevalent even in those with early recovery of consciousness after...
5.
Armand S, Langley C, Johansen A, Ozenne B, Overgaard-Hansen O, Larsen K, et al.
Sci Rep
. 2024 Feb;
14(1):3149.
PMID: 38326352
Short-term intake of selective serotonin reuptake inhibitors (SSRIs) modulates threat-related amygdala responses in healthy individuals. However, how SSRI intake over a clinically relevant time period modulates threat-related amygdala responses is...
6.
Hovmand O, Jensen M, Sogaard Juul T, Korsbak Madsen M, MacDonald Fisher P, Stenbaek D
J Psychoactive Drugs
. 2024 Jan;
57(1):37-46.
PMID: 38225795
Research suggests positive changes in both well-being and psychiatric symptoms following a psychedelic experience. One explanation may be the ability of psychedelic compounds to occasion mystical-type experiences. The Revised Mystical...
7.
Bruzzone S, Nasser A, Aripaka S, Spies M, Ozenne B, Jensen P, et al.
Sci Rep
. 2023 Sep;
13(1):16426.
PMID: 37777558
The serotonin transporter (5-HTT) critically shapes serotonin neurotransmission by regulating extracellular brain serotonin levels; it remains unclear to what extent 5-HTT levels in the human brain are genetically determined. Here...
8.
Jensen K, Dam V, Ganz M, MacDonald Fisher P, Ip C, Sankar A, et al.
BMC Psychiatry
. 2023 Mar;
23(1):151.
PMID: 36894940
Background: Major Depressive Disorder (MDD) is a heterogenous brain disorder, with potentially multiple psychosocial and biological disease mechanisms. This is also a plausible explanation for why patients do not respond...
9.
Burmester D, Korsbak Madsen M, Szabo A, Aripaka S, Stenbaek D, Frokjaer V, et al.
Compr Psychoneuroendocrinol
. 2022 Dec;
13:100163.
PMID: 36545240
Rationale: Psilocybin is a serotonergic psychedelic that has gained prominent attention recently as a potential therapeutic for neuropsychiatric disorders including Major Depressive Disorder. Pre-clinical and initial studies in humans suggest...
10.
Sondergaard A, Korsbak Madsen M, Ozenne B, Armand S, Knudsen G, MacDonald Fisher P, et al.
Front Psychol
. 2022 Oct;
13:948729.
PMID: 36275302
Background: Psilocybin-induced mystical-type experiences are associated with lasting positive psychological outcomes. Recent studies indicate that trait mindfulness is increased 3 months after psilocybin intake, preceded by decreases in neocortical serotonin...